Rationale Benzodiazepines (BZDs) are prescribed to reduce anxiety, agitation, and muscle spasms and for their sedativehypnotic and anticonvulsant effects. Under specific conditions, BZDs escalate aggression in some individuals. Specific effects of BZDs have been linked to the α-subunit subtype composition of GABA A receptors. Objectives Point-mutated mice rendered selectively insensitive to BZDs at α1-, α2-, or α3-containing GABA A receptors were used to determine which α-subunit subtypes are necessary for BZDs to escalate aggression and social approach and to reduce fear-motivated behavior. Methods During resident-intruder confrontations, male wild-type (WT) and point-mutated α1(H101R), α2(H101R), and α3(H126R) mice were treated with midazolam (0-1.7 mg/kg, i.p.) and evaluated for aggression in an unfamiliar environment. Separate midazolam-treated WT and point-mutated mice were assessed for social approach toward a female or investigated in a 6-day fear-potentiated startle procedure. Results Moderate doses of midazolam (0.3-0.56 mg/kg, i.p.) escalated aggression in WT and α3(H126R) mutants and increased social approach in WT and α1(H101R) mice. The highest dose of midazolam (1.0 mg/kg) reduced fearpotentiated startle responding. All mice were sensitive to the sedative effect of midazolam (1.7 mg/kg) except α1(H101R) mutants.
regions such as the amygdala and hypothalamus which modulate aggression (Clement et al. 1987; Haller et al. 1998; Bjork et al. 2001; Halasz et al. 2002; Toth et al. 2010; Feja and Koch 2014) . While low doses of BZDs may disrupt these pathways by acting on GABAergic neurons to facilitate neural disinhibition, higher doses generally inhibit neurotransmission to produce a calming or sedative effect (Rudolph and Knoflach 2011) .
Functionally, BZDs increase GABA A receptor-mediated chloride ion influx and potentiate agonist-induced inhibitory postsynaptic potentials (IPSPs; Wieland et al. 1992; Macdonald and Olsen 1994; Campo-Soria et al. 2006; Gielen et al. 2012) . In the mammalian central nervous system, most GABA A receptors are comprised of two α 1-6 , two β 1-3 , and one γ 1-3 subunit. GABA A receptors composed of α 1-3,5 βγ subunits can be positively modulated by benzodiazepines at a binding site between α and γ subunits.
Linking the distinct behavioral effects of BZDs to GABA A receptor subunit subtypes has been facilitated by genetic knock-in techniques that target particular subunits. In genetically modified mice, GABA A receptors are rendered selectively insensitive to BZD binding and modulation via α-subunit-specific histidine to arginine point substitutions (e.g., α1(H101R), α2(H101R), or α3(H126R); Wieland et al. 1992; Benson et al. 1998; Rudolph et al. 1999; Low et al. 2000; McKernan et al. 2000) . Using these knock-in mice, preclinical studies suggest that α1-containing GABA A receptors mediate the sedative-hypnotic and, in part, the anticonvulsant effects of benzodiazepines; α2-containing GABA A receptors mediate their reward-enhancing and anxiolytic effects; and α2-and α3-containing GABA A receptors mediate their myorelaxant activity (Low et al. 2000; Crestani et al. 2000; Crestani et al. 2001; Dixon et al. 2008; Rudolph and Knoflach 2011; Reynolds et al. 2012; Smith et al. 2012; Engin et al. 2014; Ralvenius et al. 2015) . Diazepam may also attenuate risk assessment and conditioned fear responding by acting on α2-containing GABA A receptors (Morris et al. 2006; Smith et al. 2012; Koester et al. 2013) .
Since reduced anxiety, fear, and risk assessment may be related to behavioral disinhibition and escalated aggression, we hypothesized that BZD-sensitive α2-containing GABA A receptors may be necessary for BZD-escalated aggression. To test this hypothesis, we treated male wild-type, α1(H101R), α2(H101R), and α3(H126R) knock-in mice with a benzodiazepine, midazolam, and assessed their aggression, social approach, and fear-potentiated startle (FPS) responses. Identification of GABA A receptor subtype(s) involved in BZDescalated aggression may provide important clues for the development of subtype-specific compounds that provide the therapeutic effects of BZDs without facilitating violent outbursts.
Methods Animals
Mutant α1(H101R), α2(H101R), or α3(H126R) mice were homozygous for histidine to arginine point substitutions in the α subunit protein sequence, rendering them selectively insensitive to benzodiazepines at α1-, α2-, or α3-containing GABA A receptors, respectively (Rudolph et al. 1999; Low et al. 2000) . Founders were generated and bred to a C57BL/ 6J background (Bar Harbor, ME) for at least 15 generations. Male and female C57BL/6J wild-type mice were purchased from Jackson Breeding Laboratories (Bar Harbor, ME) and bred to generate wild-type control mice (WT). For aggression and social approach experiments, mutant and WT mice were maintained in filial breeding pairs in clear polycarbonate cages (28×17×14 cm) with pine shavings at the Tufts Psychopharmacology Laboratory (Medford, MA). Breeding pairs generated F1-F8 offspring that were weaned on PPD21 and grouphoused (n>2/cage) by sex. No more than two mice per litter were assigned to the same experimental group. Each experiment evaluated contemporary wild-type, α1(H101R), α2(H101R), and α3(H126R) mutant mice.
For the social instigation and aggression protocols, 21-23 g male Swiss-Webster mice (CFW; Charles River Breeding Laboratories, Wilmington, MA) were used as stimulus animals (n=80). CFW mice were group-housed in large clear polycarbonate cages (48×27×17 cm) with corn cob bedding. All mice accessed tap water and rodent chow (LabDiet 5001 Purina Rodent Diet) freely through wire mesh cage lids. The vivarium (21±1°C, 30-40 % humidity) was kept on a 12-h photocycle (lights off 0700 h), and all behavioral assessments were made between 1000 and 1500 h when mice were most active.
Fear-potentiated startle was assessed in adult male mutant and WT mice that were bred in the Laboratory of Genetic Neuropharmacology at McLean Hospital (Belmont, MA). After weaning, animals were grouphoused by genotype in Super Mouse 750 cages containing a LifeSpan Rodent Enrichment insert (Lab Products, Seaford, DE, USA) and covered by micro-isolator nonwire bar lids. All animals had unrestricted access to food (Purina LabDiet 5P76, PMI Nutrition International, Brentwood, MO, USA) and water and were assessed for fear-potentiated startle during the light phase of the 12-h photocycle (lights off 0600 h). At the conclusion of all experiments, tail samples were collected and genotypes were confirmed using PCR. Animals were cared for according to the NIH Guide for the Care and Use of Laboratory Animals (eighth ed., 2011), and protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of Tufts University or the IACUC of McLean Hospital.
Home cage resident-intruder aggression
Eight-week-old resident mutant or wild-type males [n=14 WT; n = 16 α1(H101R); n = 12 α2(H101R); n = 14 α3(H126R)] were housed with breeding females to foster species-typical territorial aggression. After 3 weeks, resident aggression was assessed using the social instigation method (Fish et al. 1999) followed by the resident-intruder protocol every 48 h. The female and any pups were temporarily removed from the resident home cage prior to the introduction of a group-housed CFW stimulus male within a perforated, protective cage (17×6×6 cm). After 5 min, the stimulus male's cage was removed and promptly replaced with a specific, free-roaming CFW intruder male to initiate the residentintruder confrontation. Aggressive encounters were terminated 5 min after the resident initiated the first attack bite or at 5 min if the resident failed to attack (Miczek and O'Donnell 1980) .
If social instigation successfully elicited aggressive behavior in the resident male, all subsequent resident-intruder confrontations were performed in the absence of the instigation procedure. The latency to the initial attack bite and the frequency of attack bites were recorded to evaluate each resident for stable levels of aggression, operationally defined as <20 % variability within the last three encounters that were not preceded by the social instigation procedure. Animals were excluded if they were not aggressive after three consecutive resident-intruder confrontations or if they were unable to achieve stable levels of aggression after six to eight residentintruder confrontations. There was no significant difference between genotypes in terms of the proportion of mice that exhibited stable levels of aggression: 64.3 % WT; 75 % α1(H101R); 66.7 % α2(H101R); 64.3 % α3(H126R); χ 2 (2, N=56)=0.55, p=0.91.
Aggression in a novel environment with midazolam treatment
Compared to aggression in the home cage, a novel environment reduces aggressive behavior by approximately 50 % (Miczek and O'Donnell 1980; Fish et al. 1999 ). This suppressed level of aggression may facilitate the detection of behavioral disinhibition following treatment with benzodiazepines (Miczek and O'Donnell 1980) . To assess whether midazolam can disinhibit aggressive behavior, resident males were evaluated for aggression in a large, unfamiliar environment [n=9 WT; n=12 α1(H101R); n=8 α2(H101R); n=9 α3(H126R)]. The resident male was removed from his home cage and placed in one corner of an unfamiliar polycarbonate cage (84×51×42 cm) lined with fresh pine shavings. Five seconds later, the intruder was placed in the opposite corner. Like home cage encounters, confrontations in the unfamiliar environment were terminated 5 min after the first attack bite.
To eliminate any pheromonal cues, the unfamiliar cage was rinsed with water and lined with fresh pine shavings between each aggressive encounter. Resident-intruder confrontations occurred every 48 h and alternated between the resident's home cage and the unfamiliar cage until the frequency of attack bites stabilized in each environmental condition (Fig. 1) . Each resident then established a stable level of aggression toward a new intruder male over the course of four home cage confrontations. These new resident-intruder pairs remained constant during the subsequent assessments of aggression after midazolam treatment.
Residents were administered midazolam HCl (0.0, 0.1, 0.3, 0.56, 1.0, 1.7 mg/kg; Sigma-Aldrich) 15 min prior to residentintruder confrontations in the unfamiliar environment. Vehicle (0.9 % saline) and drug doses were administered intraperitoneally (i.p.) in an injection volume of 10 ml/kg of body weight. All animals received vehicle and the five randomized doses of midazolam in a mixed two-way repeated-measures experimental design. Throughout the experiment, cages were cleaned weekly at least 24 h prior to resident-intruder confrontations.
Aggressive encounters were video-recorded with a JVC Everio GZ-MG670 digital camera and later coded by a trained observer using The Observer XT software (Noldus, v. 9.0.436, Wageningen, The Netherlands). A specialized keyboard was used to code the frequency of aggressive behaviors including attack bites and sideways threats and the duration of nonaggressive behaviors included grooming, walking, rearing, and allogrooming. The total duration of time that a resident spent grooming, sniffing, or walking over or under his intruder male was termed allogrooming. Midazolam-induced sedation was operationally defined as a significant reduction in multiple behaviors including locomotion as compared to vehicle.
Social approach in an unfamiliar environment with midazolam treatment
Eight-week-old male mutant and WT mice [n=11 WT; n=11 α1(H101R); n=9 α2(H101R); n=9 α3(H126R)] were individually housed for 1 week prior to social approach testing. To minimize cues that may motivate experimental males to engage in either sexual or aggressive behavior during social approach testing, unfamiliar, group-housed, ovariectomized (OVX), WT females (n=20) served as stimulus animals. Weekly social approach assessments were conducted in a three-chamber apparatus (each chamber, 29×29×36 cm).
Prior to testing, male mice were moved from the vivarium and allowed to habituate to the procedure room for at least 1 h. At that time, the central chamber doors were lowered remotely by slowly pressurizing two air pistons, one attached to the top of either door. An OVX mouse was placed in the wire stimulus cage (11 cm height, 10.5 cm base diameter; Nadler et al. 2004) , leaving the opposite cage empty. The male habituated to the central chamber for 5 min, then received a systemic injection of 0.9 % saline or midazolam HCl (0.1, 0.3, 0.56, 1.0, 1.7 mg/kg, i.p; Sigma-Aldrich) and was returned to the central chamber. Thirteen minutes following the drug injection, the central chamber doors were lifted, allowing the male to explore the three-chamber apparatus for 10 min. EthoVision XT 8.5 was used to track the experimental male and to quantify his distance travelled (cm) and his time spent within the social approach zone surrounding the base of the occupied stimulus cage. The social approach zone extended 2.25 cm past the radius of the stimulus cage base. Between trials, the apparatus was thoroughly cleaned, and the OVX stimulus animal was replaced to prevent the transfer of pheromonal cues between male mice. During the first 2 weeks, mice were administered saline and evaluated for side preference in the absence of an OVX mouse. No experimental male mice continued to express a side preference after the second assessment, and therefore, all males were subsequently evaluated for social approach following systemic midazolam administration.
Fear-potentiated startle testing with midazolam treatment
Eight-week-old male mutant and WT mice [n=11-18/dose W T; n = 12-1 3/ do s e α 1 ( H 1 0 1R ) ; n = 10-1 3 / d os e α2(H101R); n=14-15/dose α3(H126R)] were habituated to the behavioral suite 2 h prior to testing. Fear-potentiated startle was measured using the MedAssociates Inc. (St. Albans, VT, USA) Startle Reflex System and Advanced Startle software program according to a 6-day protocol (Smith et al. 2011; Smith et al. 2012 ). Prior to the presentation of auditory stimuli, mice were first allowed to habituate to the test chamber for 5 min.
Startle amplitude data from three consecutive acclimation days were used to identify an auditory stimulus intensity (dB) that would elicit a moderate, unconditioned startle response (days 1-3). As shown previously (Smith et al. 2011; Smith et al. 2012) , the 20-ms 85-dB stimulus produced moderate startle amplitudes and was therefore used as the experimental auditory startle stimulus on days 4-6. During pre-conditioning (day 4), mice were habituated to the startle stimulus through the presentation of ten consecutive bursts. Subsequent bursts were intermittently preceded by a tone (3-s rise from 0 to 70 dB, then 27 s, 12 kHz, 70 dB). After the ten habituation bursts, startle amplitudes were measured in response to stimuli that were preceded by a tone (tone + startle) and to stimuli that were not preceded by a tone (startle only). Subjects were assigned to a midazolam group according to their matched pre-conditioning startle amplitude data (Brown et al. 1951; Smith et al. 2011) . The next day, mice were conditioned to associate the tone (CS) with a subsequent foot shock (0.25 s, 0.4 mA; US) over the course of ten CS + US trials occurring at random intervals (120, 180, or 240 s). Post-conditioning (day 6), mice were treated with midazolam HCl (0.0, 0.3, or 1.0 mg/kg i.p; Ben Venue Laboratories), and 20 min later, the pre-conditioning test was repeated.
Statistics
A two-way mixed analysis of variance (ANOVA) was performed using SigmaPlot 13.0 to assess home cage versus unfamiliar environment attack bite frequencies (genotype × environment). Two-way mixed ANOVA were also used to evaluate the frequency and duration of aggressive and nonaggressive behaviors during resident-intruder confrontations with midazolam treatment (genotype × drug treatment) and the duration of time spent in the social approach zone along with the distance travelled during social approach testing with midazolam (genotype × drug treatment).
For FPS experiments, pre-and post-conditioning startle amplitudes were calculated for each animal by averaging within habituation, startle only, or tone + startle trials. Twoway mixed ANOVA was used to detect genotype-associated differences in pre-conditioning responding to acoustic startle (genotype × trial type). To calculate the increase in startle response due to the pairing between CS and the US on day 5, fear conditioning scores were generated for each mouse according to trial type: (post-conditioning startle amplitude)-(pre-conditioning startle amplitude). A two-way mixed ANOVA was conducted on fear conditioning scores from vehicle-treated animals to assess baseline differences in fear conditioning between genotypes (genotype × trial type). For each mouse, percent FPS was used to evaluate the increase in startle response amplitude due to presentation of the tone prior to the startle stimulus on the post-conditioning test day: [((tone+startle)−(startle only))/(startle only)]×100. Two-way RM ANOVA was run on percent FPS in vehicle-treated mice to detect differences between pre-and post-conditioning values (genotype × test day). A two-way ANOVA was also performed on percent FPS (genotype × drug treatment). For all ANOVA, significant interactions and main effects were further analyzed using Dunnett's tests corrected for unequal ns (mutant genotypes vs. WT; midazolam doses vs. vehicle). For all analyses, p < 0.05 was considered statistically significant.
Results

Suppression of aggressive behavior in an unfamiliar environment
Aggressive behavior decreased when resident-intruder confrontations were in an unfamiliar environment rather than in the resident's home cage [(F(1, 33) =74.80, p<0.001); Fig. 1 ]. There was no effect of genotype (F=0.332, p=0.8) or any effect of an interaction between genotype and cage condition on aggression (F=0.124, p=0.95).
Effects of midazolam on aggression in an unfamiliar environment
There was a significant interaction between drug treatment and genotype [F(15, 165) =3.27, p<0.001]. Compared to vehicle, a moderate dose of midazolam (0.3 mg/kg) significantly increased aggression in WT and α3(H126R) mutant mice (Fig. 2e) . Conversely, midazolam-escalated aggression was absent in both α1(H101R) and α2(H101R) mutants (Fig. 2a, c) . Planned contrasts also identified reduced aggression following treatment with a high dose of midazolam (1.7 mg/kg) in WT, α2(H101R), and α3(H126R) mutant mice (Fig. 2c, e) . Reduced aggression was not observed in mice with benzodiazepine-insensitive α1-containing GABA A receptors (Fig. 2a) . ANOVA on sideways threat frequency detected an interaction between midazolam and genotype [F(15, 165)=2.54, p=0.002]. Low to moderate doses of midazolam (0.3-1.0 mg/kg) reduced the frequency of sideways threats exhibited by α1(H101R) mutants as compared to WT mice (Table 1) .
Drug treatment and genotype interacted [F(15, 165)=6.96, p<0.001] to decrease walking behavior in WT, α2(H101R) and α3(H126R) mutant mice administered the highest dose of midazolam (1.7 mg/kg; Table 1 ). Post hoc comparisons between WT and mutant mice revealed that a moderate dose of midazolam (0.56 mg/kg) could reduce motor activity in α2(H101R) mutants (Table 1) . In stark contrast, α1(H101R) mutants remained ambulatory even after treatment with the highest dose of midazolam (1.7 mg/kg). A main effect of drug treatment reduced the frequency of tail rattles [F(5, 165)= 10.26, p<0.001] after treatment with the highest doses of midazolam (1.0 and 1.7 mg/kg). Interestingly, midazolam increased the duration of allogrooming [F(5, 165)= 12.20, p<0.001] when administered in high doses. This effect appears to be specific to social grooming considering drug treatment did not increase the duration of self-grooming (Table 1) .
Effects of midazolam on social approach in an unfamiliar environment
There was a significant interaction between midazolam treatment and genotype [F(12, 144)=3.19, p<0.001]. Dunnett's post hoc comparisons revealed increased time spent in the social approach zone by WT mice and α1(H101R) mutants after treatment with a moderate dose of midazolam (0.56 mg/kg; Fig. 2b ). Additional planned contrasts identified reduced social approach behavior in α2(H101R) and α3(H126R) mutants administered the 1.0 mg/kg dose of midazolam (Fig. 2d, f) . Table 2 ): an effect that was not detected in WT mice or α1(H101R) mutants. To characterize the descending limb of the midazolam dose-effect curve in WT and α1(H101R) mutant mice, these animals were assigned to an additional social approach test after treatment with 1.7 mg/kg midazolam. Extending the dose range did not alter the statistical findings reported for social approach time. However, two-way RM ANOVA performed on distance travelled in WT mice and α1(H101R) mutants revealed a significant main effect of drug dose [F(5, 100)=26.786, p<0.001]. Planned post hoc comparisons confirmed that this effect was driven by reduced distance travelled following treatment with the highest dose of midazolam (1.7 mg/kg; Table 2 ).
Effects of midazolam on fear-potentiated startle
Pre-conditioning startle amplitudes in response to the 85-dB acoustic startle stimulus were similar across all genotypes, and the presentation of the tone prior to the startle stimulus did not potentiate this response on day 4, prior to fear conditioning. Two-way ANOVA on fear conditioning scores from vehicletreated mice identified a main effect of trial type [F(2, 102)= 59.043, p<0.001]; following fear conditioning, tone + startle trials elicited a greater increase in startle amplitude compared to habituation trials, regardless of genotype. Likewise, twoway RM ANOVA on percent FPS data from vehicle-treated mice detected a significant main effect of the test day with post-conditioning tests eliciting greater scores than tests that occurred prior to fear conditioning [(F(1, 51) = 55.92, p<0.001), 
Discussion
We have demonstrated that GABA A receptors containing the α1-or α2-subunit are essential target sites of action for midazolam (0.3 mg/kg) to escalate murine aggression toward a submissive, male intruder. In contrast, midazolam (0.56 mg/kg) may act on α2-or α3-containing GABA A receptors to increase social approach. In a non-social setting, midazolam (1.0 mg/kg) treatment attenuated fear-potentiated acoustic startle, an effect that was most evident in WT mice. These results indicate that BZD-sensitive α2-containing binding sites are crucial for midazolam to escalate aggressive and social approach behaviors. In the absence of benzodiazepine treatment, WT, α1(H101R), α2(H101R), and α3(H126R) mutant mice showed similar levels of suppressed aggression in the unfamiliar environment and increased startle responding following fear conditioning. Preclinical assessments using tests of unconditioned anxiety and conditioned fear highlight the importance of α2-containing GABA A receptors for the pronounced anxiolytic-like effects of diazepam and chlordiazepoxide (Low et al. 2000; Dixon et al. 2008; Smith et al. 2012; Koester et al. 2013) . The current study extends these observations and reveals that moderate doses of midazolam may act on α2-containing GABA A receptors to increase social behaviors. Additional work is necessary to determine whether this α2-subunit requirement applies to any social behavior or if it is specific to behaviors suppressed within an unfamiliar environment. In contrast with diazepam and chlordiazepoxide (Smith et al. 2012 ), midazolam may not require wild-type-like α2-containing GABA A receptors to diminish fear-potentiated startle responding. This could reflect differential pharmacokinetics between benzodiazepines, a possibility that requires further investigation. Our results also suggest that α1-containing GABA A receptors are crucial for midazolam-escalated aggression but not for the anxiolytic-like effect of midazolam in a social context. These findings partially dissociate escalated aggression from reduced social anxiety, suggesting that the anxiolytic effect of midazolam does not necessarily lead to heightened aggression.
Like diazepam and chlordiazepoxide, midazolam also requires BZD-sensitive α1-containing GABA A receptors in order to induce sedation (Rudolph et al. 1999; Ralvenius et al. 2015) . Wild-type, α2(H101R), and α3(H126R) mice showed reduced aggression after treatment with the highest dose of midazolam (1.7 mg/kg). This effect may be due to nonspecific suppression of motor behavior, and therefore, the absence of sedation in α1(H101R) mutants may explain their high levels of aggression even after treatment with the highest dose of midazolam.
In contrast to α1(H101R) and α2(H101R) mice, α3(H126R) mutants were sensitive to both the proaggressive and sedative effects of midazolam but not to the social anxiolytic-like effect. These findings reveal a double dissociation between the effects of midazolam on social behavior; α1-containing GABA A receptors are necessary for escalated aggression but not social approach, while α3-containing GABA A receptors are essential for increased social approach but not aggression. It appears that BZD-sensitive α2-containing GABA A receptors are required for midazolam-escalated aggression and social approach. It is possible that two separate, α2-subunit-rich loci independently regulate aggression and social approach behaviors. Alternatively, this pattern of results may reflect two functionally distinct pathways that either receive afferents from or send efferents to a shared, α2-subunit-rich region. GABA A receptors containing the α2-subunit are localized on the axon initial segment (AIS) of pyramidal cells in the hippocampus, dorsolateral prefrontal cortex, and possibly the amygdala (Nusser et al. 1996; Fritschy et al. 1998a; Loup et al. 1998; Kemppainen and Pitkanen 2000; Freund and Katona 2007; Cruz et al. 2009; Lewis et al. 2012; Ehrlich et al. 2013) . Future studies should assess whether midazolam application to the AIS may affect the production and rhythmicity of action potentials, particularly in the amygdala and hippocampus. In addition, it may be feasible in the future to generate mice lacking α2-containing GABA A receptors specifically at the AIS. Such a mutation could clarify the relationship between localized GABA A receptor modulation by benzodiazepines and aberrant social behavior. The present work suggests that midazolam requires α1-and α2-containing GABA A receptors in order to escalate aggression. Interestingly, pharmacological evaluations demonstrate that the α1-containing GABA A receptorselective antagonist, β-CCt, can effectively block the pro-aggressive effect of midazolam (Gourley et al. 2005) . These findings suggest that selective positive modulators acting on α2-but not α1-containing GABA A receptors may be sufficient to reduce anxiety with a diminished chance of promoting aggression. In addition, recent studies using mutant mice with triple histidine to arginine point substitutions [α1(H101R)/ α2(H101R)/α5(H105R)] show that positive allosteric modulation of α3-containing GABA A receptors may induce myorelaxation without sedation (Ralvenius et al. 2015) . Selective positive modulation of α3-containing GABA A receptors may also bypass the pro-aggressive effect of some benzodiazepines. Together, these findings indicate that α3-containing GABA A receptors could serve as an ideal target for the clinical treatment of muscle spasms without an extensive side effect profile.
Because experimental mice were generated from homozygous breeding pairs, it is possible that genotypeassociated differences in parental care may yield systematic variability in baseline behavior and sensitivity to benzodiazepines during adulthood. To minimize the impact of this limitation, mutants were backcrossed to C57BL/6J mice for more than 15 generations at which point they are theoretically congenic with WT mice. Baseline differences between mutant and WT mice have only been identified in animals on a mixed background but not in studies that have employed a multigenerational backcrossing protocol (Rudolph et al. 1999; Low et al. 2000; Smith et al. 2012) . Likewise, the present experimental work did not reveal any significant differences in aggression, social approach, or fear responding in vehicle-treated animals.
In the human population, developmental and environmental conditions may interact with GABRA2 single-nucleotide polymorphisms (SNPs) to potentially increase anxiety, impulsivity, and vulnerability to drug abuse disorders (Enoch et al. 2006; Dick et al. 2006a; Dick et al. 2006b; Dick et al. 2009; Uhart et al. 2013) . Recent evaluations identify polymorphisms in subjects suffering from cocaine or alcohol addiction (Covault et al. 2004; Edenberg et al. 2004; Lappalainen et al. 2005; Drgon et al. 2006; Covault et al. 2008; Soyka et al. 2008; Dixon et al. 2010; Li et al. 2014 ). Therefore, ongoing experiments use point-mutated mice to evaluate the relationship between α2-containing GABA A receptor sensitivity to various GABA A receptor ligands and escalated alcohol drinking (Newman et al., in preparation) .
